Atea Pharmaceuticals Inc. (AVIR)
4.42
+0.03 (0.68%)
Upcoming Events
Latest Headlines
Atea presents drug interaction data for hepatitis C treatment
May 27, 2026 7:02 AM - StreetInsider
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL C
May 27, 2026 7:00 AM - Globe NewsWire
Form 4/A Atea Pharmaceuticals, For: May 18 Filed by: Murphy Polly A.
May 21, 2026 6:30 PM - SEC Filing
Form 4 Atea Pharmaceuticals, For: May 18 Filed by: Murphy Polly A.
May 20, 2026 4:16 PM - SEC Filing
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
May 13, 2026 7:00 AM - Globe NewsWire
Form 10-Q Atea Pharmaceuticals, For: Mar 31
May 12, 2026 4:46 PM - SEC Filing
Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c
May 12, 2026 4:33 PM - StreetInsider
Form 8-K Atea Pharmaceuticals, For: May 12
May 12, 2026 4:18 PM - SEC Filing
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 4:05 PM - Globe NewsWire
Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: FMR LLC
May 6, 2026 11:02 AM - SEC Filing
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
May 5, 2026 7:00 AM - Globe NewsWire
Form DEFA14A Atea Pharmaceuticals,
April 27, 2026 4:58 PM - SEC Filing
Form DEF 14A Atea Pharmaceuticals, For: Jun 18
April 27, 2026 4:46 PM - SEC Filing
Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: VANGUARD GROUP INC
March 26, 2026 4:13 PM - SEC Filing
ReAlta names Howard Berman CEO and Kia Motesharei president and COO
March 24, 2026 8:01 AM - StreetInsider
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
March 24, 2026 8:00 AM - BizWire
Form 4 Atea Pharmaceuticals, For: Mar 11 Filed by: Corcoran Andrea
March 13, 2026 6:00 PM - SEC Filing
Full Article List
